Global Non-Steroidal Anti-inflammatory Drugs Market Size and Forecast 2024-2033|Pfizer Inc., Bayer AG, Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Assertio Therapeutics Inc

The Non-Steroidal Anti-inflammatory Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Non-Steroidal Anti-inflammatory Drugs Market:

https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

According to The Business Research Company’s Non-Steroidal Anti-inflammatory Drugs Global Market Report 2024, The non-steroidal anti-inflammatory drugs market size has grown strongly in recent years. It will grow from $19.56 billion in 2023 to $20.93 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to chronic inflammatory diseases, postoperative pain management, sports injuries, over-the-counter availability, aging population, consumer awareness.

The non-steroidal anti-inflammatory drugs market size is expected to see strong growth in the next few years. It will grow to $27.09 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to emerging pain management therapies, regulatory changes, telehealth utilization, global wellness trends, biosimilar competition, patient preferences, precision medicine approaches.. Major trends in the forecast period include over-the-counter (otc) market dominance, rising preference for cox-2 inhibitors, generics and market competition, integration of digital health technologies, integration of digital health technologies.

The growing incidence of chronic pain is expected to propel the growth of the non-steroidal anti-inflammatory drugs market going forward. Chronic pain refers to discomfort that persists for more than six months. Non-steroidal anti-inflammatory drugs are used to heal injuries and treat chronic pain. For instance, in April 2022, according to the report of the CDC (Centers for Disease Control and Prevention), a US-based government agency, chronic pain was frequently caused by arthritis that affects millions of people in the US. Approximately one in four adults with arthritis among 15 million people are experiencing severe joint pain related to arthritis. Therefore, the growing incidence of chronic pain is driving the growth of the non-steroidal anti-inflammatory drugs market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=8023&type=smp

The non-steroidal anti-inflammatory drugs market covered in this report is segmented –

1) By Route of Administration: Oral, Topical, Other Route of Administration

2) By Disease Indication: Arthritis, Migraine, Ophthalmic Diseases, Other Disease Indications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Product innovation is a key trend in the non-steroidal anti-inflammatory drugs market. Major companies operating in the non-steroidal anti-inflammatory drugs market are concentrating on creating new technology solutions. For instance, in May 2021, Ono and Seikagaku, a Japan-based company operating in non-steroidal anti-inflammatory drugs, launched JOYCLU, a 30 mg intra-articular injection. It is a formulation that uses Seikagaku’s proprietary technology to chemically bind hyaluronic acid with diclofenac (an anti-inflammatory medication). It is intended to release diclofenac in the joint via hydrolysis, is licenced for the treatment of osteoarthritis, and is predicted to relieve symptoms after a four-week intra-articular injection. It is administered directly into the joint cavity as an injection, resulting in low systemic exposure to diclofenac and a low risk of a systemic adverse drug reaction. It is the first ethical drug in Japan with the indication of osteoarthritis of the hip joint among joint function improvement agents.

The non-steroidal anti-inflammatory drugs market report table of contents includes:

1. Executive Summary

2. Non-Steroidal Anti-inflammatory Drugs Market Characteristics

3. Non-Steroidal Anti-inflammatory Drugs Market Trends And Strategies

4. Non-Steroidal Anti-inflammatory Drugs Market – Macro Economic Scenario

5. Global Non-Steroidal Anti-inflammatory Drugs Market Size and Growth

26. South America Non-Steroidal Anti-inflammatory Drugs Market

27. Brazil Non-Steroidal Anti-inflammatory Drugs Market

28. Middle East Non-Steroidal Anti-inflammatory Drugs Market

29. Africa Non-Steroidal Anti-inflammatory Drugs Market

30. Non-Steroidal Anti-inflammatory Drugs Market Competitive Landscape And Company Profiles

Top Major Players: